Dendrimers as Nonviral Vectors in Dendritic Cell-Based Immunotherapies Against Human Immunodeficiency Virus: Steps Toward Their Clinical Evaluation

Vacas-Córdoba, Enrique; Climent, Núria; Mata, F. Javier de la; Plana, Montserrat; Gómez, Rafael; Pion, Marjorie; García, Felipe; Muñoz‐Fernández, María Ángeles

doi:10.2217/nnm.14.172

Cited by 18 publications

(13 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have conjugated functional ligands to mesoporous silicon, calcium phosphate, gold, and upconversion nanoparticles for the preparation of nanovaccines that have the ability to induce CTLs-mediated antitumor immune responses 38-42. Additionally, peptide micelles, dendrimers, oncolytic virus (OVs) and artificial exosomes have entered clinical trials as DCs nanovaccines, which have immense promise for antitumor immunotherapy 43-45. Conversely, there are a variety of TSAs and surface functional molecules on tumor cell membranes, which are difficult to attain by conventional synthetic techniques.…”

Section: Modulating Antigen Presentation With Nanoparticlesmentioning

confidence: 99%

Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Owing to the fast-paced growth and cross-infiltration of oncology, immunology and molecular biology, tumor immunotherapy technology represented by immune checkpoint blockade and chimeric antigen receptor (CAR) T cell therapy has lately made remarkable advancements. In comparison with traditional chemotherapy, immunotherapy has the potential to elicit a stronger sustained antitumor immune response in those patients who have advanced malignant malignancies. In spite of the advancements made, a significant number of clinical research works have validated that an extensive proportion of cancer patients still manifest insensitivity to immunotherapy, primarily because of the immunomodulatory interactions between tumor cells and the immunosuppressive tumor microenvironment (TME), together mediating the immune tolerance of tumors and accordingly impacting the positive response to immunotherapy. The intricate immunosuppressive networks formed by stromal cells, inflammatory cells, vasculature, extracellular matrix (ECM), and their secreted cytokines in the TME, play a pivotal role in tumor immune escape. Specific blocking of inhibition pathways in the TME is expected to effectively prevent immune escape and tolerance of tumor cells in addition to their metastasis, accordingly improving the antitumor immune response at various phases of tumor growth. Emerging nanoscale targeted drug carriers truly suit this specific requirement due to their specificity, biocompatibility, and convenience of production. This review emphasizes recent attempts to remodel the tumor immune microenvironment using novel nanoparticles, which include specifically eliminating immunosuppressive cells, reprogramming immune regulatory cells, promoting inflammatory cytokines and blocking immune checkpoints. Targeted remodeling of the immunosuppressive TME using well-designed and fabricated nanoparticles provides a promising strategy for improving the effectiveness of current immunotherapy and is greatly significant.

show abstract

Section: Modulating Antigen Presentation With Nanoparticlesmentioning

confidence: 99%

Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Other methods such as the use of dendrimers, as discussed above (and [56]), have facilitated vaccine delivery to DCs in vivo. Dendrimers are branched nanopolymers that can have various functional groups on the terminal branches, allowing conjugation of multiple vaccine and activating components and targeting ligands to a single dendrimer [102]. The targeting molecules can facilitate delivery to DCs in vivo.…”

Section: Roles Of Dcs In Therapeutic Hiv Vaccinesmentioning

confidence: 99%

Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination

Robert-Guroff

2019

Viruses

View full text Add to dashboard Cite

Dendritic cells (DCs) are involved in human and simian immunodeficiency virus (HIV and SIV) pathogenesis but also play a critical role in orchestrating innate and adaptive vaccine-specific immune responses. Effective HIV/SIV vaccines require strong antigen-specific CD4 T cell responses, cytotoxic activity of CD8 T cells, and neutralizing/non-neutralizing antibody production at mucosal and systemic sites. To develop a protective HIV/SIV vaccine, vaccine regimens including DCs themselves, protein, DNA, mRNA, virus vectors, and various combinations have been evaluated in different animal and human models. Recent studies have shown that DCs enhanced prophylactic HIV/SIV vaccine efficacy by producing pro-inflammatory cytokines, improving T cell responses, and recruiting effector cells to target tissues. DCs are also targets for therapeutic HIV/SIV vaccines due to their ability to reverse latency, present antigen, and augment T and B cell immunity. Here, we review the complex interactions of DCs over the course of HIV/SIV prophylactic and therapeutic immunizations, providing new insights into development of advanced DC-targeted HIV/SIV vaccines.

show abstract

“…Thus, dendrimers have emerged as one of the promising technique for specific delivery of antigens. The dendrimers will release the antigens as controlled drug delivery vehicle thus making them more specific and potent in their activity [54].…”

Section: Dendrimers As Antigen Carriersmentioning

confidence: 99%

Dendritic platforms for biomimicry and biotechnological applications

Nagpal

Mohan

Thakur

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Dendrimers, commonly referred to as polymeric trees, offer endless opportunities for biotechnological and biomedical applications. By controlling the type, length, and molecular weight of the core, branches and end groups, respectively, the chemical functionality and topology of dendrimeric archetypes can be customized which further can be applied to achieve required solubility, biodegradability, diagnosis and other applications. Given the physicochemical variability of the dendrimers and their hybrids, this review attempts to discuss a full spectrum of recent advances and strides made by these "perfectly designed structures". An extensive biotech/biomimicry application profiling of dendrimers is provided with focus on complex archetypical designs such as protein biomimicry (angiogenic inhibitors, regenerative hydroxyapatite and collagen) and biotechnology applications. In terms of biotechnological advances, dendrimers have provided distinctive advantages in the fields of biocatalysis, microbicides, artificial lights, mitochondrial function modulation, vaccines, tissue regeneration and repair, antigen carriers and even biosensors. In addition, this review provides overview of the extensive chemo-functionalization opportunities available with dendrimers which makes them a perfect candidate for forming drug conjugates, protein hybrids, bio mimics, lipidic derivatives, metal deposits and nanoconjugates thereby making them the most multifunctional platforms for diverse biotechnological applications.

show abstract

Dendrimers as Nonviral Vectors in Dendritic Cell-Based Immunotherapies Against Human Immunodeficiency Virus: Steps Toward Their Clinical Evaluation

Cited by 18 publications

References 148 publications

Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy

Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy

Dendritic Cells in HIV/SIV Prophylactic and Therapeutic Vaccination

Dendritic platforms for biomimicry and biotechnological applications

Contact Info

Product

Resources

About